Abstract BACKGROUND & AIMS The development of accurate non-invasive tests to detect and measure the extent of fibrosis and disease activity in patients with non-alcoholic steatohepatitis (NASH) – the progressive phenotype of non-alcoholic fatty liver disease (NAFLD) – is of great clinical importance. Herein, we aimed to validate the performance of PRO-C3 and ADAPT for […]
Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
December 1, 2021
J Hepatol